Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently disclosed stock transactions in a filing with the Securities and Exchange Commission. On February 13, ...

Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.4 billion biopharmaceutical company with strong financials and a healthy current ratio of 3.4, sold 13,831 shares of ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $190.00. The company’s shares closed ...

In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Volatile trading persisted on the stock market last week as ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported Ingrezza Q4 about 1% below consensus estimates ...

Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market capitalization of $12.41 billion, a price-to-earnings ratio of 37.27 and a beta of 0.33.

Shares of Neurocrine Biosciences stock opened at $122.62 on Friday. The firm’s 50-day simple moving average is $138.81 and its 200-day simple moving average is $131.52. The firm has a market cap ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...